Introduction: Diabetes and cancer are common, chronic and life-threatening diseases that coexist frequently. In addition, many cancer patients are already diabetic or are developing hyperglycemia as a result of a tumor or anti-cancer therapies. The aim of our work was to evaluate the glycemic balance of diabetic patients with cancer and its impact on the prognosis of the disease. Patients and methods: This are a prospective study carried out within the endocrinology department of IBN ROCHD CHU Casablanca, in one year from 20172018. The statistical analysis done by SPSS version 25.0.
Results: We included in our study 69 patients, mean age of 56.3±12.45 years with a male predominance of 55%. An average BMI of 23.6±5.3 kg/m2, an average HBA1c (9.7%) with a self-monitoring glycemic (30.4%) and an irregular follow-up (76%). Degenerative complications include retinopathy (43.5%), nephropathy (20.3%), neuropathy (27.5%), hypertension (20%). Ketosis decompensation (40.6%). The treatment for diabetes consisted of insulin therapy (72.5%) and oral antidiabetic drugs (24.7%) with insulin therapy in 15.7%. A frequency of glycemic surveillance (52.3%). The cancers found were cerebral (2), Stomatological (2), Thyroid (2), Bone (2), Urinary (3), Digestive (5), Pancreas (6), Otorhinolaryngology (7), Pulmonary (8), Gynecology -mammary (10), Hematologic (22). After adjuvant treatment, observed remission (14.5%), healing (4.35%). Glycated hemoglobin was strongly correlated with cancer prognosis (Poor 37.7%, [RR] 0.59, 95% confidence interval [CI] 0.42-0.73, P<0.0001), but not related to risk of infection ([RR]: 0.0026, 95% confidence interval [CI]: -0.28 to 0.18, P=0.67).
Discussion/Conclusion: Diabetes and cancer comorbidity requires rigorous management in order to optimize self-management and to obtain an appropriate glycemic balance in this context of particular clinical fragility and to improve the vital prognosis of these patients which can be engaged in acute complications of diabetes or opportunistic infections.
18 - 21 May 2019
European Society of Endocrinology